Wellington Management Group LLP Has $242.30 Million Holdings in Vaxcyte, Inc. $PCVX

Key Points

• Wellington Management Group LLP increased its holdings in Vaxcyte, Inc. by 44.4%, acquiring an additional 1,972,918 shares to own approximately 4.97% of the company's stock, valued at about $242 million.
• Vaxcyte's stock has received multiple favorable ratings from analysts, with a consensus rating of "Buy" and a target price of $136.50.
• The company reported a loss of ($1.22) EPS for the last quarter, which was below the consensus estimate, and is expected to post a loss of -4.21 earnings per share for the current fiscal year.

Wellington Management Group LLP grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 44.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,416,930 shares of the company's stock after purchasing an additional 1,972,918 shares during the quarter. Wellington Management Group LLP owned approximately 4.97% of Vaxcyte worth $242,303,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Bridgefront Capital LLC boosted its stake in Vaxcyte by 4.2% during the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock worth $347,000 after acquiring an additional 172 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after purchasing an additional 293 shares in the last quarter. Avior Wealth Management LLC raised its holdings in Vaxcyte by 5.3% in the first quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock worth $257,000 after purchasing an additional 343 shares during the period. US Bancorp DE boosted its position in shares of Vaxcyte by 7.2% during the first quarter. US Bancorp DE now owns 5,344 shares of the company's stock worth $202,000 after purchasing an additional 357 shares in the last quarter. Finally, Xponance Inc. raised its holdings in Vaxcyte by 4.7% during the 1st quarter. Xponance Inc. now owns 9,320 shares of the company's stock worth $352,000 after buying an additional 415 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Wall Street Analyst Weigh In

Separately, Cowen restated a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company. According to MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Stock Up 1.2%

Shares of NASDAQ PCVX traded up $0.38 during mid-day trading on Friday, reaching $32.29. 1,519,128 shares of the company were exchanged, compared to its average volume of 1,369,275. The stock has a market capitalization of $4.19 billion, a P/E ratio of -7.86 and a beta of 1.21. The company's 50-day simple moving average is $33.64 and its 200-day simple moving average is $44.41. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter last year, the business posted ($1.10) EPS. As a group, equities research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.